Clinical diagnostics, classification;Klinische diagnostik, klassifikation

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 1, 2003, Pages 21-23

  Schreiber, S ^a   Folsch U R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CROHN DISEASE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE CLASSIFICATION; INTESTINE MUCOSA PERMEABILITY; SHORT SURVEY;

ACUTE DISEASE; ADULT; BIOLOGICAL MARKERS; CHILD; COLONOSCOPY; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY; FOLLOW-UP STUDIES; GENETIC MARKERS; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MUTATION; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0037260995     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36662     Document Type: Short Survey

References (26)

1. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease Nature 2001; 411: 599-603 (III)
2. Hampe J, Cuthbert A, Croucher PJP et al. An insertion mutation in the NOD2 gene predisposes to Crohn's Disease in the German and British populations Lancet 2001; 357: 1925-1928 (III)
3. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 2001; 411: 603-606 (III)
4. Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease Gastroenterology 2002; 122: 867-874 (III)
5. Hampe J, Grebe J, Nikolaus S et al. The NOD2 genotype and the clinical course of Crohn's disease Lancet 2002; 359: 1661-1665 (III)
6. Mascheretti S, Hampe J, Kühbacher T et al. Pharmacogenetic Investigation of the TNF/TNF-Receptor System in Patients with Chronic Active Crohn's Disease Treated with Infliximab Pharmacogenomics J 2002; 2: 127-136 (III)
7. Mascheretti S, Hampe J, Croucher PJP et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials Pharmacogenetics 2002; 12: 509-515 (III)
8. Fischbach W, Becker W, Mossner J et al. Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases Gut 1987; 28: 386-393 (III)
9. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease Gastroenterology 2000; 119: 15-22 (III)
10. Brignola C, Campieri M, Bazzochi G et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease Gastroenterology 1986; 91: 1490-1494 (III)
11. Wyatt J, Vogelsang H, Hubl W et al. Intestinal permeability and the prediction of relapse in Crohn's disease Lancet 1993; 341: 1437-1439 (III)
12. Schreiber S, Nikolaus S, Hampe J et al. Tumor Necrosis Factor-a and Interleukin 1β in Relapse of Crohn's Disease Lancet 1999; 353: 459-461 (III)
13. Nikolaus S, Raedler A, Sfikas N et al. Mechanisms in failure of infliximab for Crohn's disease Lancet 2000; 356: 1475-1479 (IIb)
14. van Oostayen JA, Wasser MN, Griffioen G et al. Diagnosis of Crohn's ileitis and monitoring of disease activity: Value of Doppler ultrasound of superior mesenteric artery flow Am J Gastroenterol 1998; 92: 88-91 (III)
15. Ludwig D, Wiener S, Bruening A et al. Mesenteric blood flow is related to disease activity and risk of relapse in Crohn's disease: A prospective follow up study Am J Gastroenterol 1999; 94: 2942-2950 (III)
16. Heyne R, Ricke S, Bock P et al. Non-invasive evaluation of activity in inflammatory bowel disease by Power Doppler sonography Z Gastroenterol 2002; 40: 171-175 (III)
17. Umschaden HW, Szolar D, Gasser J et al. Small-bowel disease: Comparison of MR enteroclysis images with concentional enteroclysis and surgical findings Radiology 2000; 215: 717-725 (III)
18. GETAID represented by Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective, multicentre study Gut 1989; 30: 983-89 (III)
19. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer 2001; 91: 854-862 (III)
20. Rubio CA, Befrits R. Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study Dis Colon Rectum 1997; 40: 1072-1078 (III)
21. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study Gastroenterology 1976; 70: 439-444 (III)
22. Goebell H, Wienbeck M, Schomerus H et al. Evaluation of the Crohn's Disease Activity Index (CDAI) and the Dutch Index for severity and activity of Crohn's disease. An analysis of the data from the European Cooperative Crohn's Disease Study Med Kli 1990; 85: 573-576 (III)
23. van Hees PA, van Elteren PH, van Lier HJ et al. An index of inflammatory activity in patients with Crohn's disease Gut 1980; 21: 279-286 (III)
24. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity Lancet 1980; 1: 514 (III)
25. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: Report of the Working Party for the World Congress of Gastroenterology, Vienna 1998 Inflamm Bowel Dis 2000; 6: 8-15 (IV)
26. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease Gut 2001; 49: 777-782 (III)